BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dy GK, Krook JE, Green EM, Sargent DJ, Delaunoit T, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol. 2007;25:3469-3474. [PMID: 17687151 DOI: 10.1200/jco.2007.10.7128] [Cited by in Crossref: 45] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Dy GK, Hobday TJ, Nelson G, Windschitl HE, O’Connell MJ, Alberts SR, Goldberg RM, Nikcevich DA, Sargent DJ. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. Clin Colorectal Cancer. 2009;8:88-93. [PMID: 19739269 DOI: 10.3816/ccc.2009.n.014] [Cited by in Crossref: 45] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
2 Tsai WS, Hsieh PS, Yeh CY, Chiang JM, Tang R, Chen JS, Changchien CR, Wang JY. Long-term survival benefits of adjuvant chemotherapy by decreasing incidence of tumor recurrence without delaying relapse in stage III colorectal cancer. Int J Colorectal Dis. 2011;26:1329-1338. [PMID: 21556841 DOI: 10.1007/s00384-011-1214-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
3 Eadens MJ, Grothey A. Curable metastatic colorectal cancer. Curr Oncol Rep. 2011;13:168-176. [PMID: 21298372 DOI: 10.1007/s11912-011-0157-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
4 Ma B, King AD, Leung L, Wang K, Poon A, Ho WM, Mo F, Chan CML, Chan ATC, Wong SCC. Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria. Ann Oncol 2017;28:1576-81. [PMID: 28379285 DOI: 10.1093/annonc/mdx149] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
5 Tu LC, Foltz G, Lin E, Hood L, Tian Q. Targeting stem cells-clinical implications for cancer therapy. Curr Stem Cell Res Ther 2009;4:147-53. [PMID: 19442199 DOI: 10.2174/157488809788167373] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
6 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 2007;13:6231-5. [PMID: 18069765 DOI: 10.3748/wjg.v13.i46.6231] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
7 Tanaka K, Ichikawa Y, Endo I. Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review. Int J Clin Oncol. 2011;16:452-463. [PMID: 21786210 DOI: 10.1007/s10147-011-0291-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
8 Binder S, Lewis AL, Löhr JM, Keese M. Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy. World J Gastroenterol 2013;19:7586-93. [PMID: 24282349 DOI: 10.3748/wjg.v19.i43.7586] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol. 2007;13:6231-6235. [PMID: 18069765 DOI: 10.3748/wjg.13.6231] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Duraj FF, Cashin PH. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal and hepatic metastases: a case-control study. J Gastrointest Oncol 2013;4:388-96. [PMID: 24294511 DOI: 10.3978/j.issn.2078-6891.2013.026] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
11 Akhtar R, Chandel S, Sarotra P, Medhi B. Current status of pharmacological treatment of colorectal cancer. World J Gastrointest Oncol. 2014;6:177-183. [PMID: 24936228 DOI: 10.4251/wjgo.v6.i6.177] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
12 Jazić I, Schrag D, Sargent DJ, Haneuse S. Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research. J Natl Cancer Inst 2016;108:djw154. [PMID: 27381741 DOI: 10.1093/jnci/djw154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
13 Tsai WS, Hsieh PS, Yeh CY, Chiang JM, Tang R, Chen JS, Changchien CR, Wang JY. Impact of chemotherapy-related prognostic factors on long-term survival in patients with stage III colorectal cancer after curative resection. Int J Clin Oncol 2013;18:242-53. [PMID: 22262452 DOI: 10.1007/s10147-011-0370-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
14 Downs-Canner S, Shuai Y, Ramalingam L, Pingpank JF, Holtzman MP, Zeh HJ, Bartlett DL, Choudry HA. Safety and efficacy of combined resection of colorectal peritoneal and liver metastases. J Surg Res 2017;219:194-201. [PMID: 29078882 DOI: 10.1016/j.jss.2017.05.126] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
15 Ferrero A, Langella S, Russolillo N, Vigano’ L, Lo Tesoriere R, Capussotti L. Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease. J Gastrointest Surg. 2012;16:806-814. [PMID: 22258869 DOI: 10.1007/s11605-011-1810-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
16 Goldberg RM, Sargent DJ, Morton RF, Green E, Sanoff HK, McLeod H, Buckner J. NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. Oncologist 2009;14:970-8. [PMID: 19828593 DOI: 10.1634/theoncologist.2009-0175] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]